drugset / Trial / NCT01701674
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
Completed
13 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Bristol-Myers Squibb · collabIovance Biotherapeutics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
Purpose of this Pilot Study: The investigators want to study the safety, side effects, and benefits of tumor infiltrating lymphocytes (TILs), when they are given with the drug ipilimumab. Ipilimumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.
Timeline
- Start
- 2012-10-09
- Primary completion
- 2016-04-21
- Completion
- 2025-08-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | IL-2 | Protein / enzyme biologic | — | Intravenous |